Mereo BioPharma
London, United Kingdom

Mereo BioPharma develops and commercialises innovative therapeutics addressing rare diseases. It also has specialty pharmaceutical products that it will partner. The assets are acquired or licensed in at clinical stages from large pharmaceutical companies. The portfolio consists of six compounds that are in clinical development.

Investment Perspective

Mereo BioPharma has reported encouraging interim results from BPS-804’s Phase IIb trial in osteogenesis imperfecta (OI). Interim data from the open label arm of the 112-patient ASTEROID study showed a 1.4% improvement over baseline in the primary endpoint at three months and a 3.2% improvement at six months. The secondary endpoint showed a 3.5% improvement at six months. Clearly the sample size in this study arm is small (11 and 12 patients), but these data suggest the 12 month results (expected in Q419) should show further improvement. Importantly, no cardiac safety signals were noted. We value Mereo BioPharma at 506p/share or $25.59/ADS.

Market information



Accelerated approval path for NAVI
Lighthouse | 16 Jul 2019
Encouraging interim BPS-804 data in OI
Update | 31 May 2019
Focus shifts back to imminent data
Update | 08 May 2019

Recent News

Setrusumab Phase IIb data to be presented at ASBMR 2019 meeting
04 Sep 2019
Appointment of Head of Pharmaceutical Development
16 Jul 2019
Successful Type B Meeting with U.S. FDA
15 Jul 2019
Conversion of loan note and issue of equity
21 Jun 2019